Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: High B3GALT5 expression confers poor clinical outcome and contributes to tumor progression and metastasis in breast cancer

Fig. 1

Expression levels of B3GALT5 in tumor and adjacent non-tumor parts of breast cancer tissues. The mRNA expression levels of B3GATL5 in breast cancer tissues (n = 202) were determined by qRT-PCR. The CT value of each specimen was normalized to the average of control and presented as minus delta threshold cycle (−dCt). a, b The values of −deltaCt of B3GALT5 in tumor part (a) and adjacent non-tumor part (b) of cancer tissues of breast cancer patients with luminal A, luminal B, Her2, and TNBC types were compared by Kruskal–Wallis test with Dunn multiple comparison. c, d The values of −deltaCt of B3GALT5 in tumor part (a) and adjacent non-tumor part (b) of cancer tissues of breast cancer patients with luminal A, luminal B, Her2, and TNBC types were compared by Kruskal–Wallis test with Dunn multiple comparison. c, d The values of −deltaCt of B3GALT5 in tumor part (c) and adjacent non-tumor part (d) of cancer tissues of breast cancer patients with non-TNBC and TNBC types were compared by Mann–Whitney U test and t test (not equal variance), respectively

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us